News & Updates

Ultraviolet (UV)-B phototherapy does not appear to increase the risk of skin cancer in patients with atopic dermatitis (AD), reveals a study.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Exposure to high levels of fine particulate matter (PM2.5) appears to contribute to an increased risk of oestrogen receptor (ER)-positive breast cancer, as shown in a study.

In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.

Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.

In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).

Pancreatic cancer, recognized as a silent yet potent malignancy, stands among the most lethal forms of cancer. Although ranking as the twelfth most prevalent cancer diagnosed globally, it claims the seventh highest fatality rate, with a disappointing 5 to 10 percent 5-year survival rate. [Available at https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis Accessed on 30 August 2023]  According to the Global Cancer Observatory 2020 (Globocan) report by the WHO, Malaysia had 1,089 new cases of pancreatic cancer, resulting in 1,066 fatalities. Notably, the incidence was calculated at approximately two individuals per 100,000.